NGL Fine Chem Ltd
Incorporated in 1981, NGL Fine-Chem Ltd is a manufacturer and exporter of pharmaceuticals and intermediates for usage in veterinary and human health.[1]
- Market Cap ₹ 928 Cr.
- Current Price ₹ 1,504
- High / Low ₹ 2,161 / 957
- Stock P/E 51.8
- Book Value ₹ 453
- Dividend Yield 0.12 %
- ROCE 8.29 %
- ROE 6.68 %
- Face Value ₹ 5.00
Pros
Cons
- Stock is trading at 3.32 times its book value
- Company has a low return on equity of 10.5% over last 3 years.
- Earnings include an other income of Rs.11.3 Cr.
- Dividend payout has been low at 4.72% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 79 | 88 | 96 | 100 | 114 | 153 | 152 | 258 | 319 | 275 | 329 | 359 | 372 | |
| 68 | 73 | 74 | 74 | 92 | 121 | 129 | 181 | 253 | 246 | 284 | 333 | 346 | |
| Operating Profit | 11 | 15 | 22 | 25 | 22 | 32 | 23 | 77 | 66 | 29 | 45 | 27 | 26 | 
| OPM % | 14% | 17% | 23% | 26% | 19% | 21% | 15% | 30% | 21% | 10% | 14% | 7% | 7% | 
| -1 | 2 | 0 | 1 | 3 | 4 | 1 | 9 | 13 | 8 | 16 | 10 | 11 | |
| Interest | 2 | 2 | 2 | 1 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 
| Depreciation | 2 | 3 | 3 | 3 | 5 | 6 | 7 | 7 | 8 | 8 | 8 | 9 | 10 | 
| Profit before tax | 7 | 13 | 18 | 23 | 18 | 28 | 14 | 76 | 69 | 27 | 51 | 24 | 24 | 
| Tax % | 32% | 35% | 36% | 35% | 29% | 27% | 26% | 27% | 24% | 24% | 24% | 24% | |
| 5 | 8 | 11 | 15 | 13 | 20 | 11 | 55 | 52 | 20 | 39 | 18 | 18 | |
| EPS in Rs | 7.33 | 13.48 | 18.45 | 24.10 | 20.38 | 32.58 | 17.16 | 89.79 | 84.57 | 32.57 | 62.35 | 29.35 | 29.04 | 
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 5% | 10% | 2% | 2% | 5% | 3% | 6% | 
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% | 
| 5 Years: | 19% | 
| 3 Years: | 4% | 
| TTM: | 7% | 
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 10% | 
| 5 Years: | 8% | 
| 3 Years: | -30% | 
| TTM: | -53% | 
| Stock Price CAGR | |
|---|---|
| 10 Years: | 20% | 
| 5 Years: | 11% | 
| 3 Years: | -1% | 
| 1 Year: | -24% | 
| Return on Equity | |
|---|---|
| 10 Years: | 19% | 
| 5 Years: | 18% | 
| 3 Years: | 11% | 
| Last Year: | 7% | 
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 
| Reserves | 21 | 30 | 41 | 56 | 69 | 89 | 98 | 152 | 203 | 222 | 260 | 277 | 
| 17 | 13 | 14 | 23 | 27 | 27 | 28 | 16 | 30 | 32 | 34 | 76 | |
| 15 | 21 | 19 | 20 | 31 | 23 | 26 | 34 | 41 | 30 | 56 | 70 | |
| Total Liabilities | 56 | 67 | 78 | 102 | 129 | 142 | 156 | 206 | 278 | 288 | 353 | 426 | 
| 19 | 17 | 24 | 25 | 56 | 61 | 61 | 58 | 59 | 59 | 60 | 120 | |
| CWIP | 0 | 1 | 2 | 16 | 3 | 0 | 0 | 1 | 6 | 26 | 46 | 50 | 
| Investments | 0 | 2 | 3 | 6 | 6 | 9 | 14 | 33 | 32 | 43 | 57 | 63 | 
| 37 | 46 | 49 | 55 | 63 | 73 | 80 | 115 | 180 | 159 | 190 | 193 | |
| Total Assets | 56 | 67 | 78 | 102 | 129 | 142 | 156 | 206 | 278 | 288 | 353 | 426 | 
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | 8 | 8 | 10 | 22 | 9 | 20 | 27 | 13 | 32 | 11 | 17 | |
| -4 | -3 | -10 | -10 | -21 | -10 | -19 | -24 | -13 | -24 | -17 | -16 | |
| 3 | -4 | 2 | 0 | 0 | 0 | -1 | -1 | -1 | -1 | -1 | -1 | |
| Net Cash Flow | -1 | 1 | 0 | -0 | 1 | -1 | -0 | 2 | -1 | 7 | -7 | 0 | 
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 110 | 107 | 123 | 110 | 89 | 79 | 63 | 53 | 74 | 86 | 92 | 81 | 
| Inventory Days | 77 | 106 | 90 | 114 | 134 | 106 | 154 | 132 | 133 | 69 | 99 | 95 | 
| Days Payable | 105 | 150 | 122 | 139 | 187 | 92 | 114 | 94 | 84 | 59 | 110 | 105 | 
| Cash Conversion Cycle | 82 | 63 | 91 | 85 | 35 | 93 | 103 | 91 | 124 | 97 | 82 | 71 | 
| Working Capital Days | 35 | 38 | 49 | 45 | 18 | 70 | 63 | 71 | 89 | 67 | 71 | 51 | 
| ROCE % | 24% | 29% | 37% | 34% | 22% | 28% | 15% | 52% | 35% | 12% | 19% | 8% | 
Documents
Announcements
- 
        
          Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
          
            3 Oct - Reg.74(5) certificate for dematerialisation during 01-Jul-2025 to 30-Sep-2025, listing confirmed.
- Closure of Trading Window 26 Sep
- 
        
          Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
          
            19 Aug - AGM on 19 Aug 2025: all eight resolutions passed; final dividend Rs1.75/share; MD reappointment; auditor appointments.
- Shareholder Meeting / Postal Ballot-Outcome of AGM 19 Aug
- 
        
          Regulation 30 Updates
          
            7 Aug - Rs.119.83 Cr invested in plant expansion for future growth in Q1 FY 2025-26.
Annual reports
- 
    
      Financial Year 2025
      from bse
- 
    
      Financial Year 2024
      from bse
- 
    
      Financial Year 2023
      from bse
- 
    
      Financial Year 2022
      from bse
- 
    
      Financial Year 2021
      from bse
- 
    
      Financial Year 2020
      from bse
- 
    
      Financial Year 2019
      from bse
- 
    
      Financial Year 2018
      from bse
- 
    
      Financial Year 2017
      from bse
- 
    
      Financial Year 2016
      from bse
- 
    
      Financial Year 2015
      from bse
- 
    
      Financial Year 2014
      from bse
- 
    
      Financial Year 2013
      from bse
- 
    
      Financial Year 2012
      from bse
- 
    
      Financial Year 2011
      from bse
Concalls
- 
      Aug 2025TranscriptNotesPPT
- 
      May 2025Transcript PPT
- 
      Feb 2025TranscriptNotesPPT
- 
      Nov 2024Transcript PPT
- 
      Aug 2024TranscriptNotesPPT
- 
      Jun 2024Transcript PPT REC
- 
      May 2024TranscriptNotesPPT
- 
      Feb 2024TranscriptNotesPPT
- 
      Nov 2023TranscriptPPT
- 
      Nov 2023Transcript PPT REC
- 
      Aug 2023TranscriptNotesPPT
- 
      May 2023Transcript PPT
- 
      Feb 2023TranscriptNotesPPT
- 
      Nov 2022Transcript PPT
- 
      Aug 2022Transcript PPT
- 
      May 2022Transcript PPT
- 
      Feb 2022Transcript PPT
- 
      Nov 2021Transcript PPT
- 
      Aug 2021Transcript PPT
- 
      Jun 2021TranscriptNotesPPT
- 
      Jun 2021Transcript PPT
- 
      Nov 2020TranscriptPPT
- 
      Jul 2020TranscriptPPT
- 
      Dec 2019TranscriptPPT
Business Overview:[1][2]
NGLFCL primarily manufactures veterinary pharmaceutical APIs and intermediates, catering to the antiprotozoal and anthelmintic therapeutic segments. Its products are used in the animal healthcare industry.
Product Profile:[3][4]
It has ~39 APIs (37 Veterinary APIs, 2 Human APIs), ~4 Intermediates, and ~12 finished dosage forms, etc., in the categories of Anthelmintics, Antiprotozoals, Ectoparasiticides, and Phosphorus Supplements